Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 89 entries
Sorted by: Best Match Show Resources per page
A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells.

Angewandte Chemie (International ed. in English)

Liu W, Cao W, Geng ZZ, Wang N, Pan Q, Guo S, Zhou J, Xu S.
PMID: 34783141
Angew Chem Int Ed Engl. 2021 Nov 15; doi: 10.1002/anie.202109550. Epub 2021 Nov 15.

As a revolutionary cancer treatment, the chimeric antigen receptor (CAR) T cell therapy suffers from complications such as cytokine release syndromes and T cell exhaustion. Their mitigation desires controllable activation of CAR-T cells that is achievable through regulatory display...

Cite
Liu W, Cao W, Geng ZZ, et al. A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells. Angew Chem Int Ed Engl. 2021;doi: 10.1002/anie.202109550.
Liu, W., Cao, W., Geng, Z. Z., Wang, N., Pan, Q., Guo, S., Zhou, J., & Xu, S. (2021). A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells. Angewandte Chemie (International ed. in English), . https://doi.org/10.1002/anie.202109550
Liu, Wenshe, et al. "A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells." Angewandte Chemie (International ed. in English) vol. (2021). doi: https://doi.org/10.1002/anie.202109550
Liu W, Cao W, Geng ZZ, Wang N, Pan Q, Guo S, Zhou J, Xu S. A Recurring Chemogenetic Switch for Chimeric Antigen Receptor T Cells. Angew Chem Int Ed Engl. 2021 Nov 15; doi: 10.1002/anie.202109550. Epub 2021 Nov 15. PMID: 34783141.
Copy Download .nbib Format: NLM
Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China.

Frontiers in pharmacology

Xia H, Lu C, Wang Y, Zaongo SD, Hu Y, Wu Y, Yan Z, Ma P.
PMID: 32508646
Front Pharmacol. 2020 May 19;11:710. doi: 10.3389/fphar.2020.00710. eCollection 2020.

OBJECTIVE: Toward the limited real-world data concerning the treatment response to brand direct-acting antiviral agents (DAAs) therapy, we proposed to evaluate the efficacy and safety of DAAs for the treatment of chronic hepatitis C virus (HCV) in mainland China.METHODS:...

Cite
Xia H, Lu C, Wang Y, et al. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Front Pharmacol. 2020;11:710doi: 10.3389/fphar.2020.00710.
Xia, H., Lu, C., Wang, Y., Zaongo, S. D., Hu, Y., Wu, Y., Yan, Z., & Ma, P. (2020). Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Frontiers in pharmacology, 11710. https://doi.org/10.3389/fphar.2020.00710
Xia, Huan, et al. "Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China." Frontiers in pharmacology vol. 11 (2020): 710. doi: https://doi.org/10.3389/fphar.2020.00710
Xia H, Lu C, Wang Y, Zaongo SD, Hu Y, Wu Y, Yan Z, Ma P. Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China. Front Pharmacol. 2020 May 19;11:710. doi: 10.3389/fphar.2020.00710. eCollection 2020. PMID: 32508646; PMCID: PMC7248196.
Copy Download .nbib Format: NLM
Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation.

Hepatology research : the official journal of the Japan Society of Hepatology

Omichi K, Akamatsu N, Mori K, Togashi J, Arita J, Kaneko J, Hasegawa K, Sakamoto Y, Kokudo N.
PMID: 27875005
Hepatol Res. 2017 Oct;47(11):1093-1101. doi: 10.1111/hepr.12845. Epub 2016 Dec 15.

AIM: This study aimed to clarify the efficacy and safety of interferon-free therapy using asunaprevir and daclatasvir, or sofosbuvir and ledipasvir for post living donor liver transplantation (LDLT) recipients with hepatitis C virus (HCV).METHODS: A retrospective cohort study of...

Cite
Omichi K, Akamatsu N, Mori K, et al. Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation. Hepatol Res. 2016;47(11):1093-1101doi: 10.1111/hepr.12845.
Omichi, K., Akamatsu, N., Mori, K., Togashi, J., Arita, J., Kaneko, J., Hasegawa, K., Sakamoto, Y., & Kokudo, N. (2017). Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation. Hepatology research : the official journal of the Japan Society of Hepatology, 47(11), 1093-1101. https://doi.org/10.1111/hepr.12845
Omichi, Kiyohiko, et al. "Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,11 (2017): 1093-1101. doi: https://doi.org/10.1111/hepr.12845
Omichi K, Akamatsu N, Mori K, Togashi J, Arita J, Kaneko J, Hasegawa K, Sakamoto Y, Kokudo N. Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation. Hepatol Res. 2017 Oct;47(11):1093-1101. doi: 10.1111/hepr.12845. Epub 2016 Dec 15. PMID: 27875005.
Copy Download .nbib Format: NLM
Rapid, direct, and sensitive determination of aziridine and 2-chloroethylamine by hydrophilic interaction liquid chromatography-mass spectrometry.

MethodsX

Shackman JG.
PMID: 31667117
MethodsX. 2019 Sep 18;6:2176-2180. doi: 10.1016/j.mex.2019.09.017. eCollection 2019.

A rapid HILIC-MS method was developed for measuring the genotoxic impurities aziridine and 2-chloroethylamine. Sample preparation was simple and direct without requiring derivatization. Paired with a 1.5 min isocratic UHPLC separation, sample analysis could be completed in less than...

Cite
Shackman JG. Rapid, direct, and sensitive determination of aziridine and 2-chloroethylamine by hydrophilic interaction liquid chromatography-mass spectrometry. MethodsX. 2019;6:2176-2180doi: 10.1016/j.mex.2019.09.017.
Shackman, J. G. (2019). Rapid, direct, and sensitive determination of aziridine and 2-chloroethylamine by hydrophilic interaction liquid chromatography-mass spectrometry. MethodsX, 62176-2180. https://doi.org/10.1016/j.mex.2019.09.017
Shackman, Jonathan G. "Rapid, direct, and sensitive determination of aziridine and 2-chloroethylamine by hydrophilic interaction liquid chromatography-mass spectrometry." MethodsX vol. 6 (2019): 2176-2180. doi: https://doi.org/10.1016/j.mex.2019.09.017
Shackman JG. Rapid, direct, and sensitive determination of aziridine and 2-chloroethylamine by hydrophilic interaction liquid chromatography-mass spectrometry. MethodsX. 2019 Sep 18;6:2176-2180. doi: 10.1016/j.mex.2019.09.017. eCollection 2019. PMID: 31667117; PMCID: PMC6812333.
Copy Download .nbib Format: NLM
Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus.

Hepatology communications

Shrivastava S, Bhatta M, Ward H, Romani S, Lee R, Rosenthal E, Osinusi A, Kohli A, Masur H, Kottilil S, Wilson E.
PMID: 30556035
Hepatol Commun. 2018 Sep 27;2(12):1451-1466. doi: 10.1002/hep4.1258. eCollection 2018 Dec.

Patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) have higher levels of immune activation, impaired antigen-specific responses, and accelerated fibrogenesis compared to patients monoinfected with HCV. Whether different direct-acting antiviral (DAA) combinations have differential effects...

Cite
Shrivastava S, Bhatta M, Ward H, et al. Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. Hepatol Commun. 2018;2(12):1451-1466doi: 10.1002/hep4.1258.
Shrivastava, S., Bhatta, M., Ward, H., Romani, S., Lee, R., Rosenthal, E., Osinusi, A., Kohli, A., Masur, H., Kottilil, S., & Wilson, E. (2018). Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. Hepatology communications, 2(12), 1451-1466. https://doi.org/10.1002/hep4.1258
Shrivastava, Shikha, et al. "Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus." Hepatology communications vol. 2,12 (2018): 1451-1466. doi: https://doi.org/10.1002/hep4.1258
Shrivastava S, Bhatta M, Ward H, Romani S, Lee R, Rosenthal E, Osinusi A, Kohli A, Masur H, Kottilil S, Wilson E. Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. Hepatol Commun. 2018 Sep 27;2(12):1451-1466. doi: 10.1002/hep4.1258. eCollection 2018 Dec. PMID: 30556035; PMCID: PMC6287478.
Copy Download .nbib Format: NLM
Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience.

Annals of surgical treatment and research

Kim JM, Lee KW, Sinn DH, Choi GS, Yi NJ, Kwon CHD, Suh KS, Joh JW.
PMID: 30182021
Ann Surg Treat Res. 2018 Sep;95(3):147-151. doi: 10.4174/astr.2018.95.3.147. Epub 2018 Aug 31.

PURPOSE: The proportion of liver recipients with HCV is gradually increasing in Korea. Limited data are available regarding the efficacy of direct antiviral agents (DAAs) in liver transplant recipients in Asia. We aimed to assess the efficacy and safety...

Cite
Kim JM, Lee KW, Sinn DH, et al. Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience. Ann Surg Treat Res. 2018;95(3):147-151doi: 10.4174/astr.2018.95.3.147.
Kim, J. M., Lee, K. W., Sinn, D. H., Choi, G. S., Yi, N. J., Kwon, C. H. D., Suh, K. S., & Joh, J. W. (2018). Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience. Annals of surgical treatment and research, 95(3), 147-151. https://doi.org/10.4174/astr.2018.95.3.147
Kim, Jong Man, et al. "Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience." Annals of surgical treatment and research vol. 95,3 (2018): 147-151. doi: https://doi.org/10.4174/astr.2018.95.3.147
Kim JM, Lee KW, Sinn DH, Choi GS, Yi NJ, Kwon CHD, Suh KS, Joh JW. Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience. Ann Surg Treat Res. 2018 Sep;95(3):147-151. doi: 10.4174/astr.2018.95.3.147. Epub 2018 Aug 31. PMID: 30182021; PMCID: PMC6121168.
Copy Download .nbib Format: NLM
Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection.

Infectious diseases and therapy

Zhu L, Li H, Chan P, Eley T, Gandhi Y, Bifano M, Osawa M, Ueno T, Hughes E, AbuTarif M, Bertz R, Garimella T.
PMID: 29589331
Infect Dis Ther. 2018 Jun;7(2):261-275. doi: 10.1007/s40121-018-0197-y. Epub 2018 Mar 27.

INTRODUCTION: Asunaprevir (ASV) is a potent, pangenotypic, twice-daily hepatitis C virus (HCV) NS3 inhibitor indicated for the treatment of chronic HCV infection.METHODS: A population pharmacokinetic (PPK) model was developed using pooled ASV concentration data from 1239 HCV-infected subjects who...

Cite
Zhu L, Li H, Chan P, et al. Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. Infect Dis Ther. 2018;7(2):261-275doi: 10.1007/s40121-018-0197-y.
Zhu, L., Li, H., Chan, P., Eley, T., Gandhi, Y., Bifano, M., Osawa, M., Ueno, T., Hughes, E., AbuTarif, M., Bertz, R., & Garimella, T. (2018). Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. Infectious diseases and therapy, 7(2), 261-275. https://doi.org/10.1007/s40121-018-0197-y
Zhu, Li, et al. "Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection." Infectious diseases and therapy vol. 7,2 (2018): 261-275. doi: https://doi.org/10.1007/s40121-018-0197-y
Zhu L, Li H, Chan P, Eley T, Gandhi Y, Bifano M, Osawa M, Ueno T, Hughes E, AbuTarif M, Bertz R, Garimella T. Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection. Infect Dis Ther. 2018 Jun;7(2):261-275. doi: 10.1007/s40121-018-0197-y. Epub 2018 Mar 27. PMID: 29589331; PMCID: PMC5986681.
Copy Download .nbib Format: NLM
A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir.

Case reports in gastroenterology

Tarao K, Yamada K.
PMID: 28690490
Case Rep Gastroenterol. 2017 Jun 09;11(2):369-376. doi: 10.1159/000462965. eCollection 2017.

Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommended as...

Cite
Tarao K, Yamada K. A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir. Case Rep Gastroenterol. 2017;11(2):369-376doi: 10.1159/000462965.
Tarao, K., & Yamada, K. (2017). A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir. Case reports in gastroenterology, 11(2), 369-376. https://doi.org/10.1159/000462965
Tarao, Kazuo, and Yamada, Kouzo. "A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir." Case reports in gastroenterology vol. 11,2 (2017): 369-376. doi: https://doi.org/10.1159/000462965
Tarao K, Yamada K. A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir. Case Rep Gastroenterol. 2017 Jun 09;11(2):369-376. doi: 10.1159/000462965. eCollection 2017. PMID: 28690490; PMCID: PMC5498963.
Copy Download .nbib Format: NLM
Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b.

Hepatology research : the official journal of the Japan Society of Hepatology

Honda K, Seike M, Oribe J, Endo M, Arakawa M, Tokoro M, Iwao M, Mori T, Nishimura J, Takahashi Y, Omori K, Yamashita T, Muro T, Murakami K.
PMID: 29080280
Hepatol Res. 2018 Mar;48(4):255-263. doi: 10.1111/hepr.12994. Epub 2017 Nov 27.

AIMS: PCR-Invader is a highly sensitive assay for detecting non-structural protein 5A (NS5A) resistance-associated variants (RAVs) of hepatitis C virus (HCV). Here, we validated the accuracy of the semiquantitative PCR-Invader (SQ-PI) assay compared to direct sequencing (DS) for identifying...

Cite
Honda K, Seike M, Oribe J, et al. Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b. Hepatol Res. 2017;48(4):255-263doi: 10.1111/hepr.12994.
Honda, K., Seike, M., Oribe, J., Endo, M., Arakawa, M., Tokoro, M., Iwao, M., Mori, T., Nishimura, J., Takahashi, Y., Omori, K., Yamashita, T., Muro, T., & Murakami, K. (2018). Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b. Hepatology research : the official journal of the Japan Society of Hepatology, 48(4), 255-263. https://doi.org/10.1111/hepr.12994
Honda, Koichi, et al. "Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,4 (2018): 255-263. doi: https://doi.org/10.1111/hepr.12994
Honda K, Seike M, Oribe J, Endo M, Arakawa M, Tokoro M, Iwao M, Mori T, Nishimura J, Takahashi Y, Omori K, Yamashita T, Muro T, Murakami K. Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b. Hepatol Res. 2018 Mar;48(4):255-263. doi: 10.1111/hepr.12994. Epub 2017 Nov 27. PMID: 29080280.
Copy Download .nbib Format: NLM
Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients.

Experimental and therapeutic medicine

Ohashi K, Ishikawa T, Suzuki M, Abe H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, Hirosawa S, Kobayashi M, Hirosawa H, Sato K, Fukazawa T, Maruyama Y, Yoshida T.
PMID: 29399105
Exp Ther Med. 2018 Jan;15(1):970-976. doi: 10.3892/etm.2017.5488. Epub 2017 Nov 10.

Interferon-free direct acting antiviral agent regimens for chronic hepatitis C (CHC) have been developed. These regimens have shown a high rate of sustained virologic response (SVR), and a reduction in side effects during treatment is also anticipated. However, the...

Cite
Ohashi K, Ishikawa T, Suzuki M, et al. Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients. Exp Ther Med. 2017;15(1):970-976doi: 10.3892/etm.2017.5488.
Ohashi, K., Ishikawa, T., Suzuki, M., Abe, H., Koyama, F., Nakano, T., Ueki, A., Noguchi, H., Hasegawa, E., Hirosawa, S., Kobayashi, M., Hirosawa, H., Sato, K., Fukazawa, T., Maruyama, Y., & Yoshida, T. (2018). Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients. Experimental and therapeutic medicine, 15(1), 970-976. https://doi.org/10.3892/etm.2017.5488
Ohashi, Kazuki, et al. "Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients." Experimental and therapeutic medicine vol. 15,1 (2018): 970-976. doi: https://doi.org/10.3892/etm.2017.5488
Ohashi K, Ishikawa T, Suzuki M, Abe H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, Hirosawa S, Kobayashi M, Hirosawa H, Sato K, Fukazawa T, Maruyama Y, Yoshida T. Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients. Exp Ther Med. 2018 Jan;15(1):970-976. doi: 10.3892/etm.2017.5488. Epub 2017 Nov 10. PMID: 29399105; PMCID: PMC5772754.
Copy Download .nbib Format: NLM
Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.

Journal of translational internal medicine

Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA.
PMID: 28680834
J Transl Int Med. 2017 Mar 31;5(1):8-17. doi: 10.1515/jtim-2017-0007. eCollection 2017 Mar.

Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. The introduction of direct acting antiviral agents (DAAs) for its treatment represents a major advance in terms of sustained virologic response (SVR) rates and adverse...

Cite
Geddawy A, Ibrahim YF, Elbahie NM, et al. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. J Transl Int Med. 2017;5(1):8-17doi: 10.1515/jtim-2017-0007.
Geddawy, A., Ibrahim, Y. F., Elbahie, N. M., & Ibrahim, M. A. (2017). Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. Journal of translational internal medicine, 5(1), 8-17. https://doi.org/10.1515/jtim-2017-0007
Geddawy, Ayman, et al. "Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction." Journal of translational internal medicine vol. 5,1 (2017): 8-17. doi: https://doi.org/10.1515/jtim-2017-0007
Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. J Transl Int Med. 2017 Mar 31;5(1):8-17. doi: 10.1515/jtim-2017-0007. eCollection 2017 Mar. PMID: 28680834; PMCID: PMC5490957.
Copy Download .nbib Format: NLM
Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.

Experimental and therapeutic medicine

Takeda K, Noguchi R, Namisaki T, Moriya K, Akahane T, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Fujinaga Y, Tsuji Y, Kubo T, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Mitoro A, Mashitani T, Okura Y, Yamao J, Yoshiji H.
PMID: 30210615
Exp Ther Med. 2018 Sep;16(3):2743-2750. doi: 10.3892/etm.2018.6481. Epub 2018 Jul 19.

Depression is a major reason for interferon (IFN) therapy cessation. IFN-free direct-acting antiviral (DAA) therapy for depression is not well-documented. Thus, four different IFN-free regimens were assessed in genotype-1 hepatitis C virus (HCV) patients with depression. Overall, 287 HCV...

Cite
Takeda K, Noguchi R, Namisaki T, et al. Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. Exp Ther Med. 2018;16(3):2743-2750doi: 10.3892/etm.2018.6481.
Takeda, K., Noguchi, R., Namisaki, T., Moriya, K., Akahane, T., Kitade, M., Kawaratani, H., Shimozato, N., Kaji, K., Takaya, H., Sawada, Y., Seki, K., Fujinaga, Y., Tsuji, Y., Kubo, T., Sato, S., Saikawa, S., Nakanishi, K., Furukawa, M., Kitagawa, K., Ozutsumi, T., Kaya, D., Mitoro, A., Mashitani, T., Okura, Y., Yamao, J., & Yoshiji, H. (2018). Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. Experimental and therapeutic medicine, 16(3), 2743-2750. https://doi.org/10.3892/etm.2018.6481
Takeda, Kosuke, et al. "Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection." Experimental and therapeutic medicine vol. 16,3 (2018): 2743-2750. doi: https://doi.org/10.3892/etm.2018.6481
Takeda K, Noguchi R, Namisaki T, Moriya K, Akahane T, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Fujinaga Y, Tsuji Y, Kubo T, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Mitoro A, Mashitani T, Okura Y, Yamao J, Yoshiji H. Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. Exp Ther Med. 2018 Sep;16(3):2743-2750. doi: 10.3892/etm.2018.6481. Epub 2018 Jul 19. PMID: 30210615; PMCID: PMC6122593.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 89 entries